Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

CAMP4 rakes in $100 million to target regulatory RNA

by Shi En Kim
July 23, 2022 | A version of this story appeared in Volume 100, Issue 26

 

The Cambridge, Massachusetts–based biotech firm CAMP4 has raised $100 million in series B funding—a year after netting $45 million in a series A round. The company is developing therapeutics that target regulatory RNA for upregulating gene expression and has an initial focus on treating liver and neurological diseases. Its lead candidate is for Dravet syndrome, a rare genetic epilepsy in infants. It will enter clinical trials mid-2023.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.